(Q42282437)

19 October 2017

Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor. (English)

1 reference

19 October 2017

0 references

1 reference

1 reference

1 reference

Brian L Pearlman

1

1 reference

PubMed ID

23873583

19 October 2017

Carole Ehleben

series ordinal

2

1 reference

PubMed ID

23873583

19 October 2017

language of work or name

English

0 references

publication date

18 November 2013

1 reference

19 October 2017

1 reference

19 October 2017

59

1 reference

19 October 2017

1

1 reference

19 October 2017

71-77

1 reference

Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence

19 October 2017

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy

21 January 2018

1 reference

A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin

21 January 2018

1 reference

Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients.

21 January 2018

1 reference

Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting

21 January 2018

1 reference

Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin

21 January 2018

1 reference

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

21 January 2018

1 reference

Rapid virologic response: a new milestone in the management of chronic hepatitis C.

21 January 2018

1 reference

Analysis of variables and interactions among variables associated with a sustained virological response to pegylated interferon alfa-2a plus ribavirin in hepatitis C virus genotype 3-infected patients.

21 January 2018

1 reference

Low hepatitis C viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis C virus

21 January 2018

1 reference

Treating patients with HCV genotype 1 and low viraemia: more than meets the eye.

21 January 2018

1 reference

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

21 January 2018

1 reference

Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial

21 January 2018

1 reference

Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response

21 January 2018

1 reference

Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy

21 January 2018

1 reference

Combination therapy of peginterferon and ribavirin for chronic hepatitis C patients with genotype 1b and low-virus load

21 January 2018

1 reference

Peginterferon alfa-2b plus weight-based ribavirin for 24 weeks in patients with chronic hepatitis C virus genotype 1 with low viral load who achieve rapid viral response

21 January 2018

1 reference

Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial.

21 January 2018

1 reference

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care

21 January 2018

1 reference

Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C.

21 January 2018

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials

21 January 2018

1 reference

Revisiting the predictors of a sustained virologic response in the era of direct-acting antiviral therapy for hepatitis C virus

21 January 2018

1 reference

HCV genotype 1a shows a better virological response to antiviral therapy than HCV genotype 1b.

21 January 2018

1 reference

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

21 January 2018

1 reference

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

21 January 2018

1 reference

Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/HEP.26624

1 reference

19 October 2017

1 reference

PubMed ID

23873583